{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T21:04:48Z","timestamp":1783544688467,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Hepatitis C virus (HCV) causes neuropsychiatric disorders and quality of life impairment, especially in patients with cryoglobulinemic vasculitis (CV). Direct acting antivirals (DAAs) are effective in most extrahepatic HCV diseases, but limited information exists regarding the outcome of psychiatric disorders in patients with and without CV, after therapy. We aimed to evaluate psychiatric outcomes, in HCV-patients with and without CV, before and after successful DAA therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We prospectively studied DAA-treated HCV-patients, stratified into presence (CV) or absence of CV (NON-CV). Four psychometric scales were administered to assess depression (HAM-D and MADRS), anxiety (HAM-A), and mania (MRS). Short-Form-36 questionnaires evaluated quality of life.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seventy-six patients were recruited, and 47 CV and 29 NON-CV were treated with antivirals. At baseline, depression and anxiety, from mild to severe, were frequently shown, with the most advanced cases in thee CV group; no patients achieved the scores for mania. A significant improvement emerged for all the psychometric scales in the entire population and in the subgroups, after viral eradication even in the short-term outcome. The Short-Form-36 summary components showed benefits.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>After HCV eradication, the depression and anxiety scores significantly improved and severity grade generally lowered. DAA-positive effects on mental disorders should be considered part of the therapy outcome, being beneficial especially in CV patients who usually have worse baseline mental scores.\n<jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td align=\"left\" colspan=\"2\"><jats:bold>Key Points<\/jats:bold>\u2022 HCV frequently causes psychiatric disorders and an often-invalidating autoimmune\/lymphoproliferative disease called cryoglobulinemic vasculitis.\u2022 The new direct acting antivirals (DAAs) are very effective and well tolerated by HCV-patients.\u2022 This study shows DAA-induced benefits on depression and anxiety in HCV-patients that are especially evident in CV patients who usually have worse baseline mental scores.\u2022 DAA-induced benefits are observed in the short-term post-therapy follow-up, in contrast with data previously obtained in HCV patients treated with IFN-based anti-HCV therapy.<\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-021-05877-3","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T05:07:57Z","timestamp":1629349677000},"page":"147-157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and without cryoglobulinemic vasculitis"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6800-9149","authenticated-orcid":false,"given":"Laura","family":"Gragnani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3547-5092","authenticated-orcid":false,"given":"Serena","family":"Lorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4385-6250","authenticated-orcid":false,"given":"Lorenzo","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9146-9968","authenticated-orcid":false,"given":"Cristina","family":"Stasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4053-6091","authenticated-orcid":false,"given":"Marcella","family":"Visentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7171-3428","authenticated-orcid":false,"given":"Luisa","family":"Petraccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0345-1291","authenticated-orcid":false,"given":"Niccol\u00f2","family":"Marello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5990-0677","authenticated-orcid":false,"given":"Monica","family":"Monti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6745-8786","authenticated-orcid":false,"given":"Silvia","family":"Marri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5746-6475","authenticated-orcid":false,"given":"Francesco","family":"Madia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9291-2124","authenticated-orcid":false,"given":"Valdo","family":"Ricca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8552-4166","authenticated-orcid":false,"given":"Anna Linda","family":"Zignego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,19]]},"reference":[{"issue":"Suppl 3","key":"5877_CR1","doi-asserted-by":"publisher","first-page":"S201","DOI":"10.1007\/s11739-012-0825-6","volume":"7","author":"AL Zignego","year":"2012","unstructured":"Zignego AL, Gragnani L, Giannini C, Laffi G (2012) The hepatitis C virus infection as a systemic disease. Intern Emerg Med 7(Suppl 3):S201\u2013S208","journal-title":"Intern Emerg Med"},{"issue":"5","key":"5877_CR2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.autrev.2017.03.004","volume":"16","author":"AL Zignego","year":"2017","unstructured":"Zignego AL, Ramos-Casals M, Ferri C, Saadoun D, Arcaini L, Roccatello D et al (2017) International therapeutic guidelines for patients with HCV-related extrahepatic disorders A multidisciplinary expert statement. Autoimmun Rev 16(5):523\u2013541","journal-title":"Autoimmun Rev"},{"issue":"3","key":"5877_CR3","first-page":"208","volume":"315","author":"L Origgi","year":"1998","unstructured":"Origgi L, Vanoli M, Carbone A, Grasso M, Scorza R (1998) Central nervous system involvement in patients with HCV-related cryoglobulinemia. Am J Med Sci 315(3):208\u2013210","journal-title":"Am J Med Sci"},{"issue":"6","key":"5877_CR4","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.jhep.2012.07.037","volume":"57","author":"M Schaefer","year":"2012","unstructured":"Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S et al (2012) Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol 57(6):1379\u20131390","journal-title":"J Hepatol"},{"issue":"3","key":"5877_CR5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0168-8278(02)00172-1","volume":"37","author":"L Kramer","year":"2002","unstructured":"Kramer L, Bauer E, Funk G, Hofer H, Jessner W, Steindl-Munda P et al (2002) Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol 37(3):349\u2013354","journal-title":"J Hepatol"},{"issue":"1","key":"5877_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/MCG.0b013e3181b314ea","volume":"44","author":"S Sockalingam","year":"2010","unstructured":"Sockalingam S, Abbey SE, Alosaimi F, Novak M (2010) A review of sleep disturbance in hepatitis C. J Clin Gastroenterol 44(1):38\u201345","journal-title":"J Clin Gastroenterol"},{"issue":"5","key":"5877_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1365-2893.2012.01591.x","volume":"19","author":"NF Fletcher","year":"2012","unstructured":"Fletcher NF, McKeating JA (2012) Hepatitis C virus and the brain. J Viral Hepat 19(5):301\u2013306","journal-title":"J Viral Hepat"},{"issue":"6","key":"5877_CR8","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/j.1365-2893.2005.00706.x","volume":"13","author":"A Cozzi","year":"2006","unstructured":"Cozzi A, Zignego AL, Carpendo R, Biagiotti T, Aldinucci A, Monti M et al (2006) Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients. J Viral Hepat 13(6):402\u2013408","journal-title":"J Viral Hepat"},{"issue":"8","key":"5877_CR9","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.3748\/wjg.v21.i8.2269","volume":"21","author":"LE Adinolfi","year":"2015","unstructured":"Adinolfi LE, Nevola R, Lus G, Restivo L, Guerrera B, Romano C et al (2015) Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. World J Gastroenterol 21(8):2269\u20132280","journal-title":"World J Gastroenterol"},{"issue":"29","key":"5877_CR10","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.3748\/wjg.v17.i29.3369","volume":"17","author":"M Senzolo","year":"2011","unstructured":"Senzolo M, Schiff S, D\u2019Aloiso CM, Crivellin C, Cholongitas E, Burra P et al (2011) Neuropsychological alterations in hepatitis C infection: the role of inflammation. World J Gastroenterol 17(29):3369\u20133374","journal-title":"World J Gastroenterol"},{"key":"5877_CR11","first-page":"6","volume":"13","author":"C Mazzaro","year":"2021","unstructured":"Mazzaro C, Maso LD, Gragnani L, Visentini M, Saccardo F, Filippini D et al (2021) Hepatitis B virus-related cryoglobulinemic vasculitis: review of the literature and long-term follow-up analysis of 18 patients treated with nucleos(t)ide analogues from the Italian Study Group of Cryoglobulinemia (GISC). Viruses 13:6","journal-title":"Viruses"},{"issue":"11","key":"5877_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11926-019-0859-0","volume":"21","author":"A Fuentes","year":"2019","unstructured":"Fuentes A, Mardones C, Burgos PI (2019) Understanding the Cryoglobulinemias. Curr Rheumatol Rep 21(11):60","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"5877_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.autrev.2016.12.001","volume":"16","author":"LA Dutra","year":"2017","unstructured":"Dutra LA, de Souza AW, Grinberg-Dias G, Barsottini OG, Appenzeller S (2017) Central nervous system vasculitis in adults: an update. Autoimmun Rev 16(2):123\u2013131","journal-title":"Autoimmun Rev"},{"issue":"1 Suppl 75","key":"5877_CR14","first-page":"S9","volume":"31","author":"L Quartuccio","year":"2013","unstructured":"Quartuccio L, Isola M, Masolini P, Scaini P, Zani R, Tavoni A et al (2013) Health-related quality of life in severe cryoglobulinaemic vasculitis and improvement after B-cell depleting therapy. Clin Exp Rheumatol 31(1 Suppl 75):S9-14","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"5877_CR15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/apt.13090","volume":"41","author":"Z Younossi","year":"2015","unstructured":"Younossi Z, Henry L (2015) Systematic review: patient-reported outcomes in chronic hepatitis C\u2013the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther 41(6):497\u2013520","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"5877_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jhep.2014.04.003","volume":"61","author":"ZM Younossi","year":"2014","unstructured":"Younossi ZM, Stepanova M, Zeuzem S, Dusheiko G, Esteban R, Hezode C et al (2014) Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. J Hepatol 61(2):228\u2013234","journal-title":"J Hepatol"},{"issue":"1 Suppl","key":"5877_CR17","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1016\/j.jhep.2016.07.005","volume":"65","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Birerdinc A, Henry L (2016) Hepatitis C infection: a multi-faceted systemic disease with clinical, patient reported and economic consequences. J Hepatol 65(1 Suppl):S109\u2013S119","journal-title":"J Hepatol"},{"issue":"4","key":"5877_CR18","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/apt.14845","volume":"48","author":"L Gragnani","year":"2018","unstructured":"Gragnani L, Cerretelli G, Lorini S, Steidl C, Giovannelli A, Monti M et al (2018) Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis. Aliment Pharmacol Ther 48(4):440\u2013450","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"5877_CR19","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1136\/gutjnl-2018-316234","volume":"67","author":"P Cacoub","year":"2018","unstructured":"Cacoub P, Desbois AC, Comarmond C, Saadoun D (2018) Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. Gut 67(11):2025\u20132034","journal-title":"Gut"},{"issue":"9","key":"5877_CR20","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.dld.2014.05.017","volume":"46","author":"L Gragnani","year":"2014","unstructured":"Gragnani L, Fabbrizzi A, Triboli E, Urraro T, Boldrini B, Fognani E et al (2014) Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study. Dig Liver Dis 46(9):833\u2013837","journal-title":"Dig Liver Dis"},{"key":"5877_CR21","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00393-017-0356-7","volume":"77","author":"AA Shahin","year":"2018","unstructured":"Shahin AA, Zayed HS, Said M, Amer SA (2018) Efficacy and safety of sofosbuvir-based, interferon-free therapy. Z Rheumatol 77:621\u2013628","journal-title":"Z Rheumatol"},{"issue":"6","key":"5877_CR22","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1176\/appi.ajp.157.6.867","volume":"157","author":"E Dieperink","year":"2000","unstructured":"Dieperink E, Willenbring M, Ho SB (2000) Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 157(6):867\u2013876","journal-title":"Am J Psychiatry"},{"issue":"5","key":"5877_CR23","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/hep.28753","volume":"64","author":"L Gragnani","year":"2016","unstructured":"Gragnani L, Visentini M, Fognani E, Urraro T, De Santis A, Petraccia L et al (2016) Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology 64(5):1473\u20131482","journal-title":"Hepatology"},{"key":"5877_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56\u201362","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"5877_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000506879","volume":"89","author":"D Carrozzino","year":"2020","unstructured":"Carrozzino D, Patierno C, Fava GA, Guidi J (2020) The Hamilton Rating Scales for Depression: a critical review of clinimetric properties of different versions. Psychother Psychosom 89(3):133\u2013150","journal-title":"Psychother Psychosom"},{"key":"5877_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jad.2016.01.051","volume":"200","author":"KJ Rohan","year":"2016","unstructured":"Rohan KJ, Rough JN, Evans M, Ho SY, Meyerhoff J, Roberts LM et al (2016) A protocol for the Hamilton Rating Scale for Depression: item scoring rules, rater training, and outcome accuracy with data on its application in a clinical trial. J Affect Disord 200:111\u2013118","journal-title":"J Affect Disord"},{"issue":"4","key":"5877_CR27","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.2044-8260.1967.tb00530.x","volume":"6","author":"M Hamilton","year":"1967","unstructured":"Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6(4):278\u2013296","journal-title":"Br J Soc Clin Psychol"},{"issue":"2","key":"5877_CR28","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jad.2013.04.028","volume":"150","author":"M Zimmerman","year":"2013","unstructured":"Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K (2013) Severity classification on the Hamilton Depression Rating Scale. J Affect Disord 150(2):384\u2013388","journal-title":"J Affect Disord"},{"issue":"1","key":"5877_CR29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"M Hamilton","year":"1959","unstructured":"Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32(1):50\u201355","journal-title":"Br J Med Psychol"},{"issue":"1","key":"5877_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0165-0327(88)90072-9","volume":"14","author":"W Maier","year":"1988","unstructured":"Maier W, Buller R, Philipp M, Heuser I (1988) The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord 14(1):61\u201368","journal-title":"J Affect Disord"},{"key":"5877_CR31","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382\u2013389","journal-title":"Br J Psychiatry"},{"issue":"6","key":"5877_CR32","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/0028-3908(78)90022-9","volume":"17","author":"P Bech","year":"1978","unstructured":"Bech P, Rafaelsen OJ, Kramp P, Bolwig TG (1978) The mania rating scale: scale construction and inter-observer agreement. Neuropharmacology 17(6):430\u2013431","journal-title":"Neuropharmacology"},{"issue":"1","key":"5877_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1034\/j.1600-0447.2001.00244.x","volume":"104","author":"P Bech","year":"2001","unstructured":"Bech P, Baastrup PC, de Bleeker E, Ropert R (2001) Dimensionality, responsiveness and standardization of the Bech-Rafaelsen Mania Scale in the ultra-short therapy with antipsychotics in patients with severe manic episodes. Acta Psychiatr Scand 104(1):25\u201330","journal-title":"Acta Psychiatr Scand"},{"issue":"6901","key":"5877_CR34","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1136\/bmj.307.6901.449","volume":"307","author":"C Jenkinson","year":"1993","unstructured":"Jenkinson C, Wright L, Coulter A (1993) The SF 36 health survey questionnaire. \u2026if used within its limits. BMJ 307(6901):449","journal-title":"BMJ"},{"issue":"3","key":"5877_CR35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/00005650-199303000-00006","volume":"31","author":"CA McHorney","year":"1993","unstructured":"McHorney CA, Ware JE, Raczek AE (1993) The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31(3):247\u201363","journal-title":"Med Care"},{"issue":"6","key":"5877_CR36","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/sj.mp.4001600","volume":"10","author":"MC Wichers","year":"2005","unstructured":"Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharp\u00e9 S, Maes M (2005) IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 10(6):538\u2013544","journal-title":"Mol Psychiatry"},{"issue":"2","key":"5877_CR37","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jpsychores.2014.07.020","volume":"78","author":"M Huckans","year":"2015","unstructured":"Huckans M, Fuller B, Wheaton V, Jaehnert S, Ellis C, Kolessar M et al (2015) A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C. J Psychosom Res 78(2):184\u2013192","journal-title":"J Psychosom Res"},{"issue":"10","key":"5877_CR38","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/j.1365-2036.2009.04123.x","volume":"30","author":"F Schmidt","year":"2009","unstructured":"Schmidt F, Janssen G, Martin G, Lorenz R, Loeschke K, Soyka M et al (2009) Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C. Aliment Pharmacol Ther 30(10):1049\u20131059","journal-title":"Aliment Pharmacol Ther"},{"issue":"9916","key":"5877_CR39","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","volume":"383","author":"E Lawitz","year":"2014","unstructured":"Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H et al (2014) Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 383(9916):515\u2013523","journal-title":"Lancet"},{"issue":"7","key":"5877_CR40","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1136\/ard.2011.150755","volume":"70","author":"S De Vita","year":"2011","unstructured":"De Vita S, Soldano F, Isola M, Monti G, Gabrielli A, Tzioufas A et al (2011) Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis 70(7):1183\u20131190","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5877_CR41","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jhep.2013.12.006","volume":"60","author":"ZM Younossi","year":"2014","unstructured":"Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E et al (2014) Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol 60(4):741\u2013747","journal-title":"J Hepatol"},{"issue":"3","key":"5877_CR42","doi-asserted-by":"publisher","first-page":"116","DOI":"10.9740\/mhc.2018.05.116","volume":"8","author":"B Sackey","year":"2018","unstructured":"Sackey B, Shults JG, Moore TA, Rogers R, Mehvar M, King JG (2018) Evaluating psychiatric outcomes associated with direct-acting antiviral treatment in veterans with hepatitis C infection. Ment Health Clin 8(3):116\u2013121","journal-title":"Ment Health Clin"},{"issue":"1","key":"5877_CR43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12888-018-1735-6","volume":"18","author":"I Sundberg","year":"2018","unstructured":"Sundberg I, Lannerg\u00e5rd A, Ramklint M, Cunningham JL (2018) Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study. BMC Psychiatry 18(1):157","journal-title":"BMC Psychiatry"},{"issue":"3","key":"5877_CR44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/ejhpharm-2017-001352","volume":"26","author":"M Miarons","year":"2019","unstructured":"Miarons M, S\u00e1nchez-Ulayar A, Sempere G, Mar\u00edn S, Castellv\u00ed JM (2019) New direct-acting antivirals for hepatitis C treatment and neuropsychiatric symptoms in psychiatric risk groups. Eur J Hosp Pharm 26(3):135\u2013139","journal-title":"Eur J Hosp Pharm"},{"issue":"6","key":"5877_CR45","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1053\/jhep.2000.7880","volume":"31","author":"D Zdilar","year":"2000","unstructured":"Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM (2000) Hepatitis C, interferon alfa, and depression. Hepatology 31(6):1207\u20131211","journal-title":"Hepatology"},{"issue":"7","key":"5877_CR46","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/jvh.12881","volume":"25","author":"P Cacoub","year":"2018","unstructured":"Cacoub P, Buggisch P, Carri\u00f3n JA, Cooke GS, Zignego AL, Beckerman R et al (2018) Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe. J Viral Hepat 25(7):811\u2013817","journal-title":"J Viral Hepat"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05877-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05877-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05877-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T07:15:56Z","timestamp":1659770156000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05877-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,19]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["5877"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05877-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,19]]},"assertion":[{"value":"9 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Missing Open Access funding information has been added in the Funding Note.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study received institutional review board approval (evaluation code: SPE 14.084_ AOUC).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}